Identifying novel circulating biomarkers predictive of response and informative about the mechanisms of resistance, is the new challenge for breast cancer (BC) management. The integration of omics information will gradually revolutionize the clinical approach. Liquid biopsy is being incorporated into the diagnostic and decision-making process for the treatment of BC, in particular with the analysis of circulating tumor DNA, although with some relevant limitations, including costs. Circulating cell-free DNA (cfDNA) fragmentomics and its integrity index may become a cheaper, noninvasive biomarker that could provide significant additional information for monitoring response to systemic treatments in BC. The purpose of our review is to focus on the available research on cfDNA integrity and its features as a biomarker of diagnosis, prognosis and response to treatments in BC, highlighting new perspectives and critical issues for future applications.

Gianni, C., Palleschi, M., Merloni, F., Di Menna, G., Sirico, M., Sarti, S., et al. (2022). Cell-Free DNA Fragmentomics: A Promising Biomarker for Diagnosis, Prognosis and Prediction of Response in Breast Cancer. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 23(22), 1-14 [10.3390/ijms232214197].

Cell-Free DNA Fragmentomics: A Promising Biomarker for Diagnosis, Prognosis and Prediction of Response in Breast Cancer

Gianni, Caterina;Palleschi, Michela;Sirico, Marianna;Virga, Alessandra;Ulivi, Paola;De Giorgi, Ugo
2022

Abstract

Identifying novel circulating biomarkers predictive of response and informative about the mechanisms of resistance, is the new challenge for breast cancer (BC) management. The integration of omics information will gradually revolutionize the clinical approach. Liquid biopsy is being incorporated into the diagnostic and decision-making process for the treatment of BC, in particular with the analysis of circulating tumor DNA, although with some relevant limitations, including costs. Circulating cell-free DNA (cfDNA) fragmentomics and its integrity index may become a cheaper, noninvasive biomarker that could provide significant additional information for monitoring response to systemic treatments in BC. The purpose of our review is to focus on the available research on cfDNA integrity and its features as a biomarker of diagnosis, prognosis and response to treatments in BC, highlighting new perspectives and critical issues for future applications.
2022
Gianni, C., Palleschi, M., Merloni, F., Di Menna, G., Sirico, M., Sarti, S., et al. (2022). Cell-Free DNA Fragmentomics: A Promising Biomarker for Diagnosis, Prognosis and Prediction of Response in Breast Cancer. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 23(22), 1-14 [10.3390/ijms232214197].
Gianni, Caterina; Palleschi, Michela; Merloni, Filippo; Di Menna, Giandomenico; Sirico, Marianna; Sarti, Samanta; Virga, Alessandra; Ulivi, Paola; Cec...espandi
File in questo prodotto:
File Dimensione Formato  
graphic.pdf

accesso aperto

Tipo: File Supplementare
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione 417.83 kB
Formato Adobe PDF
417.83 kB Adobe PDF Visualizza/Apri
ijms-23-14197.pdf

accesso aperto

Tipo: Versione (PDF) editoriale
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione 613.98 kB
Formato Adobe PDF
613.98 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/953411
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 11
  • ???jsp.display-item.citation.isi??? 10
social impact